Condition (MeSH)
Dysgerminoma
ClinicalTrials.gov lists 8 trials for Dysgerminoma or a narrower condition beneath it.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
8 of the 8 trials are tagged with Dysgerminoma itself; the rest are tagged with a narrower condition beneath it.
When did Dysgerminoma trials start? (7)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 2
- Observational
Top of scale: 2
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2023 | 1 |
| 2017 | 1 |
| 2010 | 1 |
| 2007 | 2 |
| 2006 | 1 |
| 2003 | 1 |
| 2002 | 1 |
No forecast is made for this condition: it averages 0.2 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: none of the 8 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Dysgerminoma trials in? (3)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 5 |
| Observational | 2 |
How many Dysgerminoma trials are recruiting? (3)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Active, not recruiting | 1 |
| Completed | 6 |
| Terminated | 1 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Dysgerminoma trials? (2)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Gynecologic Oncology Group | 1 |
| National Cancer Institute (NCI) | 1 |
Which serious adverse events do Dysgerminoma trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Nausea | 13 | 1 |
| Vomiting | 13 | 1 |
| Neutrophils/granulocytes | 10 | 1 |
| Febrile Neutropenia | 9 | 1 |
| Leukocytes | 6 | 1 |
Showing 5 of 10 adverse events.
Which publications cover Dysgerminoma? (7)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Testicular cancer in young men and parental occupational exposure. | American journal of industrial medicine | 1991 | Yes |
| Recovery from aspermia induced by low-dose radiation in seminoma patients. | Cancer | 1982 | Yes |
| ATAXIA-TELANGIECTASIA. | Canadian Medical Association journal | 1964 | Yes |
| Delay in diagnosis and survival in testicular cancer: impact of effective therapy and changes during 18 years. | The Journal of urology | 1990 | No |
| Acute vascular ischemic events after cisplatin-based combination chemotherapy for germ-cell tumors of the testis. | Annals of internal medicine | 1986 | No |
Showing 5 of 7 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence, rare-disease identity, and sub-conditions in mesh.
Not computed for conditions with fewer than 10 trials: drugs tested.